NASDAQ · MDCXW

Medicus Pharma Ltd.

$0.35 -$0.00 (-0.03%) 1D Market open

Key Metrics

$4.28M
Market cap
P/E · TTM
Revenue · TTM
−$3.94M
Net income
EPS · TTM $-0.32
Dividend yield
Free cash flow
Beta · 1Y -1.42
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 30
    The stock moved +85.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 30
  • Apr 28
    The stock moved +148.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 28
  • Apr 22
    From its Feb 18 high, the share price fell 73%.

    Peak close $1.06 on Feb 18; trough close $0.29 on Apr 22. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -73%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap
Enterprise value$262.31K
Shares outstanding
52-wk range$0.20 – $1.45
Avg volume · 20D5.6K
Net cash $4.02M
Book value / share$0.11
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Medicus Pharma Ltd.
IPO dateNov 14, 2024
Employees16

Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC -297.1% · —

Financial Health

Current ratio1.22
Quick ratio
Debt / equity1.77
Debt / EBITDA
Net cash $4.02M
Working capital$1.33M

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

0 / 9
Weak fundamentals · 0 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings